|
業務類別
|
Biotechnology |
|
業務概覽
|
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions. |
| 公司地址
| 701 Lee Road, Suite 103, Wayne, PA, USA, 19087 |
| 電話號碼
| +1 484 324-7933 |
| 傳真號碼
| +1 484 320-2344 |
| 公司網頁
| https://www.aclaristx.com |
| 員工數量
| 73 |
| Dr. Neal Walker, D.O. |
Chairman of the Board and Chief Executive Officer |
美元 615.00K |
23/04/2026 |
| Mr. James Loerop |
Chief Business Officer |
美元 416.00K |
23/04/2026 |
| Mr. Jesse Wayne Hall |
Chief Medical Officer |
-- |
23/04/2026 |
| Mr. Roland Wilhelm Kolbeck |
Chief Scientific Officer |
-- |
23/04/2026 |
| Mr. Kevin Balthaser |
Chief Financial Officer and Principal Accounting Officer |
美元 446.00K |
23/04/2026 |
| Dr. Hugh Davis, PhD |
President, Chief Operating Officer and Director |
-- |
23/04/2026 |
|
|
| Dr. Maxine Gowen,PhD |
Independent Director |
23/04/2026 |
| Mr. Vincent J. Milano |
Independent Director |
23/04/2026 |
| Dr. Andrew N. Schiff, M.D. |
Independent Director |
23/04/2026 |
| Dr. Anand Mehra, M.D. |
Independent Director |
23/04/2026 |
| Dr. Neal Walker, D.O. |
Chairman of the Board and Chief Executive Officer |
23/04/2026 |
| Mr. Christopher Molineaux |
Lead Independent Director |
23/04/2026 |
| Mr. William D. Humphries |
Independent Director |
23/04/2026 |
| Dr. Hugh Davis, PhD |
President, Chief Operating Officer and Director |
23/04/2026 |
|
|
|
|
